completion

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure StudyRevive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

2 weeks ago
AB Science announces the successful completion of a EUR 1.925 million private placementAB Science announces the successful completion of a EUR 1.925 million private placement

AB Science announces the successful completion of a EUR 1.925 million private placement

PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 1.925 MILLION PRIVATE PLACEMENT Paris, July 8, 2025, 8am…

2 weeks ago
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerUroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and…

2 weeks ago
Aeries Technology Announces Completion of Fiscal Year 2025 Earnings CallAeries Technology Announces Completion of Fiscal Year 2025 Earnings Call

Aeries Technology Announces Completion of Fiscal Year 2025 Earnings Call

Core Adjusted EBITDA exceeds guidance; Company re-affirms FY 2026 outlook as AI-Centric Global Capability Center strategy accelerates July 03, 2025…

2 weeks ago
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic AtrophyBelite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

July 02, 2025 03:00 ET  | Source: Belite Bio, Inc -  500 subjects enrolled across the United States, the United…

3 weeks ago
Gastops and Leeway Marine Advance Innovative Engine Oil Monitoring System with Successful Field TestingGastops and Leeway Marine Advance Innovative Engine Oil Monitoring System with Successful Field Testing

Gastops and Leeway Marine Advance Innovative Engine Oil Monitoring System with Successful Field Testing

DARTMOUTH, NS, May 26, 2025 /PRNewswire/ -- Gastops is pleased to announce the successful completion of a full season of…

1 month ago
2nd Edition of French Space Days Concludes Across India, Reinforcing Indo-French Space Collaboration2nd Edition of French Space Days Concludes Across India, Reinforcing Indo-French Space Collaboration

2nd Edition of French Space Days Concludes Across India, Reinforcing Indo-French Space Collaboration

NEW DELHI, May 26, 2025 /PRNewswire/ -- Business France India is pleased to announce the successful completion of the 2nd…

1 month ago
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today…

1 month ago
Acclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser TechnologyAcclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser Technology

Acclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser Technology

Accelmed $20 Million Investment with 3E Bioventures Capital Funding of $3 Million to Drive Innovation, Clinical Expansion, and Global Market…

2 months ago